138 related articles for article (PubMed ID: 15577325)
1. Phase II study of thalidomide in patients with metastatic malignant melanoma.
Reiriz AB; Richter MF; Fernandes S; Cancela AI; Costa TD; Di Leone LP; Schwartsmann G
Melanoma Res; 2004 Dec; 14(6):527-31. PubMed ID: 15577325
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of thalidomide in patients with metastatic breast cancer.
Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF
J Clin Oncol; 2000 Jul; 18(14):2710-7. PubMed ID: 10894870
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of thalidomide in patients with metastatic melanoma.
Pawlak WZ; Legha SS
Melanoma Res; 2004 Feb; 14(1):57-62. PubMed ID: 15091195
[TBL] [Abstract][Full Text] [Related]
5. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.
Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG
Br J Cancer; 2004 Mar; 90(5):955-61. PubMed ID: 14997189
[TBL] [Abstract][Full Text] [Related]
6. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.
Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Costa TD; Di Leone LP; Schwartsmann G
Invest New Drugs; 2003 Aug; 21(3):359-66. PubMed ID: 14578685
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Laber DA; Okeke RI; Arce-Lara C; Taft BS; Schonard CL; McMasters KM; Kloecker GH; Miller DM
J Cancer Res Clin Oncol; 2006 Sep; 132(9):611-6. PubMed ID: 16741726
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
Varker KA; Campbell J; Shah MH
Cancer Chemother Pharmacol; 2008 Apr; 61(4):661-8. PubMed ID: 17589846
[TBL] [Abstract][Full Text] [Related]
17. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SR; Ahern R; Smith IE; Gore ME
Br J Cancer; 2000 Feb; 82(4):812-7. PubMed ID: 10732751
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
[TBL] [Abstract][Full Text] [Related]
19. The treatment of advanced renal cell cancer with high-dose oral thalidomide.
Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME
Br J Cancer; 2001 Sep; 85(7):953-8. PubMed ID: 11592764
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Hurteau JA; Brady MF; Darcy KM; McGuire WP; Edmonds P; Pearl ML; Ivanov I; Tewari KS; Mannel RS; Zanotti K; Benbrook DM
Gynecol Oncol; 2010 Dec; 119(3):444-50. PubMed ID: 20846715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
